Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | BCR | P11274 | 3/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 2/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.46 |
| ▸ | CDK9 | P50750 | 5/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904242 | 0.89 | KIT (0.56) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL4892544 | 0.85 | KIT (0.69) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL1265232 | 0.81 | TEK (0.55) | KITTNNI3KALDH1A1CYP17A1KDR | |
| SCHEMBL4902265 | 0.80 | ALDH1A1 (0.53) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL4902031 | 0.79 | CCNT1 (0.50) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL6041077 | 0.78 | ALDH1A1 (0.55) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL4903706 | 0.77 | PRKCA (0.70) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL5775770 | 0.76 | PDGFRA (0.53) | KITABL1BCRPDGFRAPDGFRB | |
| SCHEMBL5263301 | 0.74 | CYP17A1 (0.40) | KITTNNI3KALDH1A1CYP17A1 | |
| SCHEMBL4903401 | 0.74 | IKBKB (0.67) | IKBKBCHUKCCNT1CDK9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | KIT 4607/4885ABL1 904/4885BCR 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.